Consolidated Statements of Operations (USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Operating Costs and Expenses:
General and administrative	$ 5,832	$ 5,012
Research and development	6,507	12,287
Total Operating Costs and Expenses	12,339	17,299
Loss from Operations	(12,339)	(17,299)
Other Income (Expense):
Interest income	33	33
Other expense	(12)	(18)
Total Other Income	21	15
Loss from Continuing Operations	(12,318)	(17,284)
Income from Discontinued Operations	0	216
Net Loss	(12,318)	(17,068)
Net Loss Attributable to Non-controlling Interest	(1)	0
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	$ (12,317)	$ (17,068)
Net Income (Loss) Per Share - Basic and Dilutive:
Continuing operations (in dollars per share)	$ (0.27)	$ (0.50)
Discontinued operations (in dollars per share)	$ 0	$ 0.01
Net Income (Loss) Per Share Attributable to Synthetic Biologics, Inc. and Subsidiaries (in dollars per share)	$ (0.27)	$ (0.49)
Weighted average number of shares outstanding during the period - Basic and Dilutive (in shares)	45,667,813	34,896,592